Quick Takeaways
- MORGAN STANLEY filed SCHEDULE 13G for UroGen Pharma Ltd. Ordinary Shares (URGN).
- Disclosed ownership: 5.4%.
- Date of event: 30 Jun 2025.
MORGAN STANLEY - 30 Jun 2025 SCHEDULE 13G Report for UroGen Pharma Ltd. Ordinary Shares (URGN)
- Filing Manager
- MORGAN STANLEY
- Reporting Manager
- Morgan Stanley
- Security
- UroGen Pharma Ltd. Ordinary Shares
- Symbol
- URGN
- Shares outstanding
- 46,079,611 shares
- Disclosed Ownership
- 2,488,299 shares
- Ownership
- 5.4%
- Form type
- SCHEDULE 13G
- Filing time
- 06 Aug 2025, 15:56:03 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 05 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MORGAN STANLEY disclosed 5.4% ownership in UroGen Pharma Ltd. Ordinary Shares (URGN) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 05 Feb 2025.
- Current filing was accepted on 06 Aug 2025, 15:56.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | 5.4% | 2,488,299 | 0 | 2,463,149 | Chris O'Hara | Authorized Signatory, Morgan Stanley |